ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,161 to 4,180 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Placebo + Prednisone 5 mg vs Orteronel 400 mg + Prednisone 5 mg: Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings130 of 770

163 of 784

-3.9 points

-7.8 to -0.0

1,554NCT01193244

Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Placebo + Prednisone 5 mg vs Orteronel 400 mg + Prednisone 5 mg: serious adverse events321 of 770

380 of 784

-6.8 points

-11.7 to -1.8

1,554NCT01193244

Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Antibiotics Therapy Arm vs Appendectomy Arm: Rates of Participants With Appendiceal Cancer4 of 776

6 of 776

-0.3 points

-1.2 to 0.6

1,552NCT02800785

The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial

Standard Implementation Plus Health Coaching vs Standard Implementation Plus Health Coaching and Practice Facilitation: Reach-26 of 296

8 of 1,256

1.4 points

0.1 to 3.7

1,552NCT04907045

An Initial Study of the Implementation of Digital Therapeutics for Substance Use Disorders in Primary Care

Standard Implementation Plus Health Coaching vs Standard Implementation Plus Health Coaching and Practice Facilitation: Reach of the Digital Therapeutic to Patients in the Primary Care Clinic1 of 296

4 of 1,256

0.0 points

-0.6 to 1.6

1,552NCT04907045

An Initial Study of the Implementation of Digital Therapeutics for Substance Use Disorders in Primary Care

Standard Implementation Plus Health Coaching vs Standard Implementation Plus Health Coaching and Practice Facilitation: Reach-31 of 296

6 of 1,256

-0.1 points

-0.8 to 1.4

1,552NCT04907045

An Initial Study of the Implementation of Digital Therapeutics for Substance Use Disorders in Primary Care

Linagliptin vs Glimepiride: serious adverse events135 of 776

162 of 775

-3.5 points

-7.4 to 0.4

1,551NCT00622284

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

Methoxy Polyethylene Glycol-epoetin Beta (Predialysis) vs Methoxy Polyethylene Glycol-epoetin Beta (Hemodialysis): serious adverse events7 of 346

67 of 1,201

-3.6 points

-5.3 to -1.2

1,547NCT01051323

An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Renal Anemia

EEG Guided vs Usual Care: ICU Admission17 of 773

15 of 774

0.3 points

-1.2 to 1.8

1,547NCT03330236

EEG - Guided Anesthetic Care and Postoperative Delirium

EEG Guided vs Usual Care: Number of Participants With Postoperative Delirium8 of 773

9 of 774

-0.1 points

-1.3 to 1.0

1,547NCT03330236

EEG - Guided Anesthetic Care and Postoperative Delirium

EEG Guided vs Usual Care: Emergence Delirium91 of 773

102 of 774

-1.4 points

-4.7 to 1.9

1,547NCT03330236

EEG - Guided Anesthetic Care and Postoperative Delirium

Empaglifozin 25 mg vs Glimepiride: The Occurrence of Confirmed Hypoglycaemic Events During 52 Weeks of Treatment.12 of 765

159 of 780

-18.8 points

-21.9 to -15.9

1,545NCT01167881

Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

Empaglifozin 25 mg vs Glimepiride: The Occurrence of Confirmed Hypoglycaemic Events During 104 Weeks of Treatment.19 of 765

189 of 780

-21.7 points

-25.0 to -18.6

1,545NCT01167881

Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

Empa 25mg vs Glimepiride: serious adverse events161 of 765

153 of 780

1.4 points

-2.6 to 5.4

1,545NCT01167881

Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

Fluid Restriction Group vs Standard-care: 90-day Mortality323 of 764

329 of 781

0.2 points

-4.8 to 5.1

1,545NCT03668236

The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial

Fluid Restriction Group vs Standard-care: deaths from any cause385 of 764

383 of 781

1.4 points

-3.6 to 6.3

1,545NCT03668236

The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial

Intervention Group vs Delay Results Group: Depression Response242 of 754

216 of 787

4.6 points

0.1 to 9.2

1,541NCT03170362

PRIME Care (PRecision Medicine In MEntal Health Care)

Intervention Group vs Delay Results Group: Depression Remission130 of 754

126 of 787

1.2 points

-2.5 to 5.0

1,541NCT03170362

PRIME Care (PRecision Medicine In MEntal Health Care)

EEG Guided vs Usual Care: Non-delirium Complications175 of 768

193 of 773

-2.2 points

-6.4 to 2.1

1,541NCT03330236

EEG - Guided Anesthetic Care and Postoperative Delirium

Restrictive Fluids vs Liberal Fluids: Death From Any Cause at Any Location by Day 90172 of 768

169 of 773

0.5 points

-3.6 to 4.7

1,541NCT03434028

Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=209"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=209

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01193244-cd2ed095",
        "title": "Placebo + Prednisone 5 mg vs Orteronel 400 mg + Prednisone 5 mg: Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings",
        "summary": "130 of 770 against 163 of 784; risk difference -3.9 points, 95% interval -7.8 to -0.0; NCT01193244, Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer",
        "record": "/library/comparisons/NCT01193244-cd2ed095",
        "nct_id": "NCT01193244",
        "kind": "outcome",
        "participants": 1554,
        "risk_difference": {
          "value": -0.039076994434137285,
          "lower": -0.07784445318261685,
          "upper": -0.00015173915671862215
        },
        "group_1": "130 of 770",
        "group_2": "163 of 784",
        "difference": "-3.9 points",
        "interval": "-7.8 to -0.0",
        "trial_title": "Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer"
      },
      {
        "id": "NCT01193244-sae",
        "title": "Placebo + Prednisone 5 mg vs Orteronel 400 mg + Prednisone 5 mg: serious adverse events",
        "summary": "321 of 770 against 380 of 784; risk difference -6.8 points, 95% interval -11.7 to -1.8; NCT01193244, Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer",
        "record": "/library/comparisons/NCT01193244-sae",
        "nct_id": "NCT01193244",
        "kind": "serious-adverse-events",
        "participants": 1554,
        "risk_difference": {
          "value": -0.06781076066790354,
          "lower": -0.11681558999114995,
          "upper": -0.018329532646512978
        },
        "group_1": "321 of 770",
        "group_2": "380 of 784",
        "difference": "-6.8 points",
        "interval": "-11.7 to -1.8",
        "trial_title": "Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=210",
  "request_id": "ON7cr6ZPWnJDr4l6"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?